Drugs / AZD7624
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01937338 | Oct 2013 → Apr 2014 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01817855 | Sep 2013 → Oct 2014 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01754844 | Jan → Aug 2013 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02238483 | Oct 2014 → Apr 2016 | chronic obstructive pulmonary disease | AstraZeneca | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02753764 Comparator | Jan 2017 → Feb 2019 | asthma | National Jewish Health | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD7624 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01817855 ↗ |
| Action | Inhibit | “ability of AZD7624 to inhibit p38 MAPK activity” NCT02753764 ↗1“MAP kinase p38 alpha inhibitor” CHEMBL9960 ↗ |
| Modality | Small molecule | — CHEMBL9960 ↗ |
| Route | Inhaled | “Single dose inhaled IMP via a nebulizer” NCT01754844 ↗ |
| Target | MAPK14 | “MAP kinase p38 alpha inhibitor” CHEMBL9960 ↗ |